Why the study?
Do pharmacologic agents improve outcomes in patients with vasovagal syncope?
Do pharmacologic agents improve outcomes in patients with vasovagal syncope?
This review highlights that despite the use of various pharmacologic agents for vasovagal syncope, only atenolol, midodrine, and paroxetine have demonstrated efficacy in randomized, placebo-controlled trials.
Answers are grounded in this paper and cite their sources.
May limit pharmacotherapy for vasovagal syncope to atenolol, midodrine, or paroxetine; leaves open efficacy of alternatives.
Vasovagal syncope is a common disorder of autonomic cardiovascular regulation. Many pharmacologic agents have been proposed as effective in the management of this condition based on nonrandomized clinical trials. Notably, only 3 agents--atenolol, midodrine, and paroxetine--have demonstrated efficacy in the treatment of vasovagal syncope in at least 1 prospective, randomized, placebo-controlled clinical trial. Other therapies commonly used in treating syncope include increased salt and fluid intake and fludrocortisone. In this review, we provide a summary of currently available data that support or question the use of various pharmacologic agents for treatment of vasovagal syncope.
No takes yet. Share an insight, caveat, or question.
Hugh Calkins (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: